Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings

B. Clemens, Andrea Ménes, Pálma Piros, Mónika Bessenyei, Anna Altmann, Judit Jerney, Katalin Kollár, Beáta Rosdy, Margit Rózsavölgyi, Katalin Steinecker, Katalin Hollódy

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy. Baseline waking EEG (EEG1) was recorded in the untreated state, the second EEG (EEG2) was done after 8 weeks of reaching the therapeutic dose. Left occipital data were used for analysis. QEEG target parameters were absolute band-power (delta: AD, theta: AT, alpha: AA, beta: AB), and alpha mean frequency (AMF). Group effects (untreated versus treated condition in the CBZ, VA, OXC, LA groups) were computed for each target parameter. One group with benign rolandic epilepsy remained untreated for clinical reasons and served to estimate the QEEG test-retest differences. In addition, the individual QEEG response to each drug was calculated as (EEG2 - EEG1). Results: statistically significant (p <0.05) group differences indicated the QEEG domain systematically affected by the drugs. CBZ caused AT increase and AMF decrease. OXC caused AMF decrease. VA and LA did not decrease AMF (LA even increased it), but reduced broad-band power. Individual power and AMF changes showed considerable variability in each group. >0.5 Hz AMF decrease (that was reported to predict cognitive impairment in prior studies) occurred in 10/41 patients in the CBZ group but never in the OXC, VA, LA groups. The results may be utilized in planning further studies addressing the relationship between antiepileptic drugs and their CNS effects. In addition, the relationship of AED-related cognitive impairment and AMF changes was discussed.

Original languageEnglish
Pages (from-to)190-199
Number of pages10
JournalEpilepsy Research
Volume70
Issue number2-3
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Carbamazepine
Valproic Acid
Electroencephalography
Rolandic Epilepsy
Therapeutic Uses
Anticonvulsants
oxcarbazepine
lamotrigine
Epilepsy
Pharmaceutical Preparations

Keywords

  • Carbamazepine
  • Cognitive impairment
  • Lamotrigine
  • Neurotoxicity
  • Oxcarbazepine
  • Quantitative EEG
  • Valproate

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. / Clemens, B.; Ménes, Andrea; Piros, Pálma; Bessenyei, Mónika; Altmann, Anna; Jerney, Judit; Kollár, Katalin; Rosdy, Beáta; Rózsavölgyi, Margit; Steinecker, Katalin; Hollódy, Katalin.

In: Epilepsy Research, Vol. 70, No. 2-3, 08.2006, p. 190-199.

Research output: Contribution to journalArticle

Clemens, B, Ménes, A, Piros, P, Bessenyei, M, Altmann, A, Jerney, J, Kollár, K, Rosdy, B, Rózsavölgyi, M, Steinecker, K & Hollódy, K 2006, 'Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings', Epilepsy Research, vol. 70, no. 2-3, pp. 190-199. https://doi.org/10.1016/j.eplepsyres.2005.11.023
Clemens, B. ; Ménes, Andrea ; Piros, Pálma ; Bessenyei, Mónika ; Altmann, Anna ; Jerney, Judit ; Kollár, Katalin ; Rosdy, Beáta ; Rózsavölgyi, Margit ; Steinecker, Katalin ; Hollódy, Katalin. / Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. In: Epilepsy Research. 2006 ; Vol. 70, No. 2-3. pp. 190-199.
@article{eddf64c4f9fb4897a74849236aaedad5,
title = "Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings",
abstract = "Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy. Baseline waking EEG (EEG1) was recorded in the untreated state, the second EEG (EEG2) was done after 8 weeks of reaching the therapeutic dose. Left occipital data were used for analysis. QEEG target parameters were absolute band-power (delta: AD, theta: AT, alpha: AA, beta: AB), and alpha mean frequency (AMF). Group effects (untreated versus treated condition in the CBZ, VA, OXC, LA groups) were computed for each target parameter. One group with benign rolandic epilepsy remained untreated for clinical reasons and served to estimate the QEEG test-retest differences. In addition, the individual QEEG response to each drug was calculated as (EEG2 - EEG1). Results: statistically significant (p <0.05) group differences indicated the QEEG domain systematically affected by the drugs. CBZ caused AT increase and AMF decrease. OXC caused AMF decrease. VA and LA did not decrease AMF (LA even increased it), but reduced broad-band power. Individual power and AMF changes showed considerable variability in each group. >0.5 Hz AMF decrease (that was reported to predict cognitive impairment in prior studies) occurred in 10/41 patients in the CBZ group but never in the OXC, VA, LA groups. The results may be utilized in planning further studies addressing the relationship between antiepileptic drugs and their CNS effects. In addition, the relationship of AED-related cognitive impairment and AMF changes was discussed.",
keywords = "Carbamazepine, Cognitive impairment, Lamotrigine, Neurotoxicity, Oxcarbazepine, Quantitative EEG, Valproate",
author = "B. Clemens and Andrea M{\'e}nes and P{\'a}lma Piros and M{\'o}nika Bessenyei and Anna Altmann and Judit Jerney and Katalin Koll{\'a}r and Be{\'a}ta Rosdy and Margit R{\'o}zsav{\"o}lgyi and Katalin Steinecker and Katalin Holl{\'o}dy",
year = "2006",
month = "8",
doi = "10.1016/j.eplepsyres.2005.11.023",
language = "English",
volume = "70",
pages = "190--199",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings

AU - Clemens, B.

AU - Ménes, Andrea

AU - Piros, Pálma

AU - Bessenyei, Mónika

AU - Altmann, Anna

AU - Jerney, Judit

AU - Kollár, Katalin

AU - Rosdy, Beáta

AU - Rózsavölgyi, Margit

AU - Steinecker, Katalin

AU - Hollódy, Katalin

PY - 2006/8

Y1 - 2006/8

N2 - Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy. Baseline waking EEG (EEG1) was recorded in the untreated state, the second EEG (EEG2) was done after 8 weeks of reaching the therapeutic dose. Left occipital data were used for analysis. QEEG target parameters were absolute band-power (delta: AD, theta: AT, alpha: AA, beta: AB), and alpha mean frequency (AMF). Group effects (untreated versus treated condition in the CBZ, VA, OXC, LA groups) were computed for each target parameter. One group with benign rolandic epilepsy remained untreated for clinical reasons and served to estimate the QEEG test-retest differences. In addition, the individual QEEG response to each drug was calculated as (EEG2 - EEG1). Results: statistically significant (p <0.05) group differences indicated the QEEG domain systematically affected by the drugs. CBZ caused AT increase and AMF decrease. OXC caused AMF decrease. VA and LA did not decrease AMF (LA even increased it), but reduced broad-band power. Individual power and AMF changes showed considerable variability in each group. >0.5 Hz AMF decrease (that was reported to predict cognitive impairment in prior studies) occurred in 10/41 patients in the CBZ group but never in the OXC, VA, LA groups. The results may be utilized in planning further studies addressing the relationship between antiepileptic drugs and their CNS effects. In addition, the relationship of AED-related cognitive impairment and AMF changes was discussed.

AB - Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy. Baseline waking EEG (EEG1) was recorded in the untreated state, the second EEG (EEG2) was done after 8 weeks of reaching the therapeutic dose. Left occipital data were used for analysis. QEEG target parameters were absolute band-power (delta: AD, theta: AT, alpha: AA, beta: AB), and alpha mean frequency (AMF). Group effects (untreated versus treated condition in the CBZ, VA, OXC, LA groups) were computed for each target parameter. One group with benign rolandic epilepsy remained untreated for clinical reasons and served to estimate the QEEG test-retest differences. In addition, the individual QEEG response to each drug was calculated as (EEG2 - EEG1). Results: statistically significant (p <0.05) group differences indicated the QEEG domain systematically affected by the drugs. CBZ caused AT increase and AMF decrease. OXC caused AMF decrease. VA and LA did not decrease AMF (LA even increased it), but reduced broad-band power. Individual power and AMF changes showed considerable variability in each group. >0.5 Hz AMF decrease (that was reported to predict cognitive impairment in prior studies) occurred in 10/41 patients in the CBZ group but never in the OXC, VA, LA groups. The results may be utilized in planning further studies addressing the relationship between antiepileptic drugs and their CNS effects. In addition, the relationship of AED-related cognitive impairment and AMF changes was discussed.

KW - Carbamazepine

KW - Cognitive impairment

KW - Lamotrigine

KW - Neurotoxicity

KW - Oxcarbazepine

KW - Quantitative EEG

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=33746930304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746930304&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2005.11.023

DO - 10.1016/j.eplepsyres.2005.11.023

M3 - Article

C2 - 16765028

AN - SCOPUS:33746930304

VL - 70

SP - 190

EP - 199

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 2-3

ER -